(NASDAQ: TRAW) Traws Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Traws Pharma's revenue in 2024 is $226,000.On average, 1 Wall Street analysts forecast TRAW's revenue for 2024 to be $115,723,548, with the lowest TRAW revenue forecast at $115,723,548, and the highest TRAW revenue forecast at $115,723,548. On average, 1 Wall Street analysts forecast TRAW's revenue for 2025 to be $6,312,194, with the lowest TRAW revenue forecast at $6,312,194, and the highest TRAW revenue forecast at $6,312,194.
In 2026, TRAW is forecast to generate $6,312,194 in revenue, with the lowest revenue forecast at $6,312,194 and the highest revenue forecast at $6,312,194.